This project has been flagged by a community member as inappropriate due to reason below.*
Slingshot & STAT have partnered to provide you with interviews with experts led by STAT's reporters. This call is on:

Reviewing Novel Mechanisms in Depression: SAGE-217 in MDD, Axsome Therapeutics' AXS-05, and Recently Approved Esketamine From JNJ.

Ticker(s): SAGE, JNJ, AXSM

Who's the expert?

Name: Dr Deborah Kim - MD

Institution: UPENN & Private Practice

  • Clinical associate professor at the Perelman School of Medicine at the University of Pennsylvania.
  • Currently manages 100s of patients with depression.
  • Specializes in the treatment of perinatal mood and anxiety disorders with extensive experience with treating patients with major medical co-morbidities, PMS/PMDD, menopausal issues and bipolar disorder.
  • Prescribes IV ketamine and is clinically certified in treating patients with TMS.

Interview Goal
This conversation will review promising new approaches and recent approvals in depression. The conversation will discuss the strengths and weaknesses of compounds in development and the current unmet medical need.

Are You Interested In These Questions?

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.